With a better understanding of the mechanisms by which parkin causes early dystonia and dyskinesia, researchers may be able to identify novel therapeutic targets and develop strategies that include drugs that act on the glutamatergic system. The gene discussed is PRKN; the disease is drug-induced dyskinesia.